Canopus Bioscience Advancing Cancer Monitoring and Therapeutic Effectiveness

Canopus develops instrumentation and methodologies that are focused on the goal of improving patient-specific diagnostics and disease management.
News:  
As part of our objective to create a strong presence in Europe we are planning a clinical study that will take place at a prestigious French Institution.

Canopus is also entering into a joint project to design precision low cost microfiltration/fluidic  devices.
This project will be utilizing leading edge manufacturing technology and will allow  the production of
these micro devices to be scaled up to very large volumes.
Les nouvelles
Dans le cadre de notre objectif d'avoir une forte présence en Europe, nous prévoyons de commencer
une étude clinique en partenariat avec un établissement français de renommée mondiale.

Canopus a conclu un projet de coopération pour concevoir un nouveau système de microfiltration de très
grande précision à un prix de revient très abordable. Ce projet fera appel à une technologie de pointe
permettant la fabrication en grandes séries.
Our superior enrichment technology is now protected by key patents
2010 US Patent #7,695,966  (granted)Method for the separation and sorting of different biological
objects utilizing differences in their viscoelastic properties
2008 PCT/EP2008/057826 (filed)Our prototype based on the patent has a sample throughput of up to 12 samples per hour and is currently being used in clinical research laboratories for the enrichment of CTCs (including cells undergoing epithelial-mesenchymal transition (EMT)) and Fetal cells.
Canopus Bioscience welcomes inquiries from potential research, licensing or marketing partners.

For additional information please email:
corporate@canopus-bioscience.com

Disclaimer: NO INFORMATION ON THE CANOPUS BIOSCIENCE, LTD. (TORONTO, CANADA) WEB SITE SHOULD BE CONSIDERED FOR
USE IN MEDICAL DIAGNOSTICS, THERAPY OR TREATMENT WITHOUT THE REQUIRED REGULATORY APPROVALS.